PMID- 38101289
OWN - NLM
STAT- MEDLINE
DCOM- 20240216
LR  - 20240216
IS  - 1094-6950 (Print)
IS  - 1094-6950 (Linking)
VI  - 27
IP  - 1
DP  - 2024 Jan-Mar
TI  - Meta-Analysis on the Association Between DPP-4 Inhibitors and Bone Mineral 
      Density and Osteoporosis.
PG  - 101455
LID - S1094-6950(23)00105-1 [pii]
LID - 10.1016/j.jocd.2023.101455 [doi]
AB  - Background Type 2 Diabetes Mellitus (T2DM) frequently coexists with osteoporosis 
      and reduced bone mineral density (BMD). Dipeptidyl peptidase-4 inhibitors 
      (DPP-4i), a class of antihyperglycemic agents, are commonly employed in T2DM 
      treatment. However, the influence of DPP-4i on bone health remains unclear and 
      debated. This meta-analysis is conducted to explore the relationship between the 
      use of DPP-4i and changes in BMD, as well as the prevalence of osteoporosis among 
      T2DM patients. Methods We conducted a comprehensive search in PubMed, Embase, and 
      Cochrane Library and Web of Science databases for relevant studies published up 
      until June 2023. Studies included in the meta-analysis were those investigating 
      T2DM patients under DPP-4i treatment, and examining the effects on BMD and 
      osteoporosis. Random-effects models and fixed-effect models were utilized to 
      compute the pooled effects. Heterogeneity among the included studies was 
      evaluated using I(2) statistics. Results This meta-analysis incorporated a total of 
      10 studies, encompassing a combined population of 214,541 individuals. The 
      results from this meta-analysis indicated an increase in BMD following DPP-4i 
      usage (SMD 0.15, 95 % confidence interval 0.03-0.26). Additionally, the risk of 
      osteoporosis was significantly reduced (OR 0.90, 95 % confidence interval 
      0.86-0.94) with very low heterogeneity, recorded at 0 % and 53.0 % respectively. 
      No publication bias was detected in the funnel plot, and sensitivity analyses 
      affirmed the stability of the study's conclusions. Conclusion Our results offer 
      valuable insights into the positive impact of DPP-4i on bone health in T2DM 
      patients, contributing to informed clinical decision-making. These findings may 
      inform the development of more comprehensive T2DM management strategies that 
      account for bone health.
CI  - Copyright (c) 2023 The Author(s). Published by Elsevier Inc. All rights reserved.
FAU - Huang, Lili
AU  - Huang L
AD  - Department of Endocrinology, The First Affiliated Hospital of Guangxi Medical 
      University, 6 Shuangyong Road, Nanning, Guangxi Zhuang Autonomous Region, 530021, 
      PR China; Department of Endocrinology, The Affiliated Hospital of Guilin Medical 
      University, 15 Lequn Road, Guilin, Guangxi Zhuang Autonomous Region, 541001, PR 
      China.
FAU - Zhong, Wei
AU  - Zhong W
AD  - Department of Neurosurgery, Guilin People's Hospital, The Fifth Affiliated 
      Hospital of Guilin Medical University, Guilin 541002, PR China.
FAU - Liang, Xinghuan
AU  - Liang X
AD  - Department of Endocrinology, The First Affiliated Hospital of Guangxi Medical 
      University, 6 Shuangyong Road, Nanning, Guangxi Zhuang Autonomous Region, 530021, 
      PR China.
FAU - Wang, Huijuan
AU  - Wang H
AD  - Department of General Medicine, Guilin People's Hospital, The Fifth Affiliated 
      Hospital of Guilin Medical University, Guilin 541002, PR China.
FAU - Fu, Shi-En
AU  - Fu SE
AD  - Department of Endocrinology, The First Affiliated Hospital of Guangxi Medical 
      University, 6 Shuangyong Road, Nanning, Guangxi Zhuang Autonomous Region, 530021, 
      PR China.
FAU - Luo, Zuojie
AU  - Luo Z
AD  - Department of Endocrinology, The First Affiliated Hospital of Guangxi Medical 
      University, 6 Shuangyong Road, Nanning, Guangxi Zhuang Autonomous Region, 530021, 
      PR China. Electronic address: luozuojie@gxmu.edu.cn.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
DEP - 20231128
PL  - United States
TA  - J Clin Densitom
JT  - Journal of clinical densitometry : the official journal of the International 
      Society for Clinical Densitometry
JID - 9808212
RN  - 0 (Dipeptidyl-Peptidase IV Inhibitors)
RN  - 0 (Hypoglycemic Agents)
SB  - IM
MH  - Humans
MH  - *Dipeptidyl-Peptidase IV Inhibitors/adverse effects
MH  - *Diabetes Mellitus, Type 2/drug therapy/epidemiology
MH  - Bone Density
MH  - Hypoglycemic Agents/therapeutic use
MH  - *Osteoporosis/drug therapy
OTO - NOTNLM
OT  - Bone mineral density
OT  - DPP-4 inhibitors
OT  - Meta-analysis
OT  - Osteoporosis
OT  - Type 2 diabetes mellitus
COIS- Declaration of Competing Interests The authors declare that they have no 
      competing interests.
EDAT- 2023/12/16 11:43
MHDA- 2024/02/16 06:42
CRDT- 2023/12/15 18:17
PHST- 2023/08/20 00:00 [received]
PHST- 2023/11/21 00:00 [revised]
PHST- 2023/11/21 00:00 [accepted]
PHST- 2024/02/16 06:42 [medline]
PHST- 2023/12/16 11:43 [pubmed]
PHST- 2023/12/15 18:17 [entrez]
AID - S1094-6950(23)00105-1 [pii]
AID - 10.1016/j.jocd.2023.101455 [doi]
PST - ppublish
SO  - J Clin Densitom. 2024 Jan-Mar;27(1):101455. doi: 10.1016/j.jocd.2023.101455. Epub 
      2023 Nov 28.